The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10267 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax malaria

Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania

October 1, 2019 - 14:27 -- Open Access
Author(s): 
Oum kelthoum Mamadou Djigo, Mohamed Abdallahi Bollahi, Moina Hasni Ebou, Mohamed Salem Ould Ahmedou Salem, Rachida Tahar, Hervé Bogreau, Leonardo Basco, Ali Ould Mohamed Salem Boukhary
Reference: 
PLoS ONE 14(9): e0220977

Primaquine is recommended by the World Health Organization (WHO) for radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to lack of data on G6PD deficiency, the use of primaquine has been limited in Africa. In the present study, G6PD deficiency was investigated in blood donors of various ethnic groups living in Nouakchott, a P. vivax endemic area in Mauritania.

Country: 
Medical Condition: 

Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy

October 17, 2012 - 07:36 -- Kabogo Ndegwa
Author(s): 
Joel Tarning, Palang Chotsiri, Vincent Jullien, Marcus J. Rijken, Martin Bergstrand, Mireille Cammas, Rose McGready, Pratap Singhasivanon, Nicholas P. J. Day, Nicholas J. White, Francois Nosten, and Niklas Lindegard
Reference: 
Antimicrob. Agents Chemother. November 2012 vol. 56 no. 11 5764-5773

MalariaWorldAmodiaquine is effective for the treatment of Plasmodium vivax malaria, but there is little information on the pharmacokinetic and pharmacodynamic properties of amodiaquine in pregnant women with malaria.

Person: 
Medical Condition: 
Medical Treatment: 

Open Access | Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature

January 11, 2012 - 08:43 -- Kabogo Ndegwa
Author(s): 
Lacerda MV, Mourao MP, Alexandre MA, Siqueira AM, Magalhaes BM, Martinez-Espinosa FE, Santana Filho FS, Brasil P, Ventura AM, Tada MS, Couto VS, Silva AR, Silva RS, Alecrim MG
Reference: 
Malaria Journal 2012, 11:12 (9 January 2012)

MalariaWorldThe resurgence of the malaria eradication agenda and the increasing number of severe manifestation reports has contributed to a renewed interested in the Plasmodium vivax infection.

Country: 

Plasmodium vivax Susceptibility to Ferroquine

April 20, 2010 - 08:57 -- Kabogo Ndegwa
Author(s): 
M. L. Leimanis, A. Jaidee, K. Sriprawat, S. Kaewpongsri, R. Suwanarusk, M. Barends, A. P. Phyo, B. Russell, L. Renia, and F. Nosten
Reference: 
Antimicrobial Agents and Chemotherapy, May 2010, p. 2228-2230, Vol. 54, No. 5

The novel organometallic chloroquine analog ferroquine (SSR 97193) is effective against chloroquine-resistant Plasmodium falciparum. The ex vivo efficacy of ferroquine against Plasmodium vivax isolates was tested. Ferroquine has a potent ex vivo effect on P. vivax schizont maturation (median 50% inhibitory concentration, 15 nM; n = 42).

Medical Condition: 
Medical Treatment: 

Case report: Retinal Hemorrhage in Plasmodium vivax Malaria

February 10, 2010 - 21:45 -- Ingeborg van Schayk
Author(s): 
Ji Hwan Lee, Hee Seung Chin, Moon-Hyun Chung, AND Yeon Sook Moon
Reference: 
Am J Trop Med Hyg 2010;82 219-222

In Plasmodium vivax infection, however, retinal hemorrhage is very rare; only five cases have been reported in the literature. In this case report, we review the literature and the case of 52-year-old man who had retinal hemorrhages in P. vivax infection.

Subscribe to RSS - Plasmodium vivax malaria